Abstract
This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia” (Version I to Version VII) made by China, “Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected—Interim guidance” made by World Health Organization (WHO), “Therapeutic Guidelines: Respiratory” published by Australia, and the origin of classical prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the dictionary of traditional Chinese medicine (Version II) manually. We search literatures from 2001 to 2020 on Wiley online library. We conduct a comparative study on the therapeutic options and indications among Qingfei Paidu Decoction, COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are considered to be basically consistent. Qingfei Paidu Decoction has a definite therapeutic effect on the symptoms, basic diseases and complications for COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of phytotherapy for severe acute respiratory infection caused by COVID-19.
Highlights
This work is aimed to study the therapeutics and pharmacology of the treatment of severe acute respiratory infection caused by coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei Paidu Decoction”
We try to compare common pharmacological effects of a group of TCM through inquiry of pharmacology with treatment options corresponding to the guideline, the pharmacological differences exist between single chemical composition and mixed decoction
The symptoms bases on TCM herbs prescriptions are consist with the symptoms at all stage of chronic obstructive pulmonary disease (COPD) in “Therapeutic Guidelines: Respiratory” published by Australia, and they are almost consist with “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Version VII)” and “Clinical management of severe acute respiratory infection when 2019-nCoV infection is suspected—Interim guidance” made by World Health Organization (WHO)
Summary
Qingfei Paidu Decoction is one of the Chinese therapeutic options for the treatment of severe acute respiratory infections caused by COVID-19, and is one of the most highly recommend phytotherapy in China. We attempt to explain the possible value of Qingfei Paidu Decoction in the epidemic in a way that can be understood. It is a new attempt, the article includes comparative studies and review. We try to compare TCM symptoms with clinical manifestations and classification of treatment guidelines, this is not one-to-one correspondence. We try to compare common pharmacological effects of a group of TCM through inquiry of pharmacology with treatment options corresponding to the guideline, the pharmacological differences exist between single chemical composition and mixed decoction. We hope this paper can bring some help to the treatment of COVID-19
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
